Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic testing instrument maker Affymetrix (NASDAQ: AFFX ) climbed 11% today after its fourth-quarter sales outlook impressed Wall Street.
So what: The stock has rocketed over the past six month on optimism over stabilizing demand, and today's preliminary fourth-quarter report only reinforces those good vibes. In fact, Affymetrix's projected revenue represents about 8% growth over the year-ago period, suggesting that its competitive position is strengthening as well.
Now what: Management now expects fourth-quarter revenue of roughly $91 million, which includes a one-time $5.3 million licensing payment from a diagnostic partner.
"In 2013 we executed effectively against our three phase strategic plan and we exited the year as a much stronger Company," said President and CEO Dr. Frank Witney. "Over the last 12 months we improved our business's performance, significantly reduced our senior debt and increased our overall cash balance."
Of course, with Affymetrix shares now up a whopping 130% since August and trading at a forward P/E of 60, much of that improvement might already be baked well into the valuation.
A more reliable way to wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.